Seattle Children's Hospital
Autologous CD19 CAR+ EGFTt + T cells(Seattle Children's Hospital)은 CD19 표적 세포·유전자 치료로, B Cell Leukemia 영역에서 개발·상용화 중입니다. 작용기전: CAR T cells by combining CRISPR/Cas9-mediated TCR knockout with mRNA-based CAR expression, and to evaluate cryopreservation s. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 1건의 관련 임상이 등록되어 있습니다. 차별점: novel and potent treatment option for carefully selected patients with severe, refractory autoimmune rheumatic diseases.
CD19
B Cell Leukemia
Recruiting
CAR T-Cell Therapy for B-Cell Lymphomas
novel and potent treatment option for carefully selected patients with severe, refractory autoimmune rheumatic diseases
CAR T cells by combining CRISPR/Cas9-mediated TCR knockout with mRNA-based CAR expression, and to evaluate cryopreservation s
cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 93% a
CD19-directed CAR-T has been associated with high rates of lupus low
downregulation of CD133 or CD19
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Seattle Children's Hospital
Autologous CD19 CAR+ EGFTt + T cells(Seattle Children's Hospital)은 CD19 표적 세포·유전자 치료로, B Cell Leukemia 영역에서 개발·상용화 중입니다. 작용기전: CAR T cells by combining CRISPR/Cas9-mediated TCR knockout with mRNA-based CAR expression, and to evaluate cryopreservation s. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 1건의 관련 임상이 등록되어 있습니다. 차별점: novel and potent treatment option for carefully selected patients with severe, refractory autoimmune rheumatic diseases.
CD19
B Cell Leukemia
Recruiting
CAR T-Cell Therapy for B-Cell Lymphomas
novel and potent treatment option for carefully selected patients with severe, refractory autoimmune rheumatic diseases
CAR T cells by combining CRISPR/Cas9-mediated TCR knockout with mRNA-based CAR expression, and to evaluate cryopreservation s
cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 93% a
CD19-directed CAR-T has been associated with high rates of lupus low
downregulation of CD133 or CD19
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.